NYSE : ACR
-$0.23 (-1.27%)
| Source | Headline |
|---|---|
|
ACRES Commercial Realty Corp. to Report Results for Second Quarter 2026
UNIONDALE, N.Y., July 15, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that it will release its results for the second quarter 2026, on Wednesday, July 29, 2026, after the market closes. prnewswire.com - 2026-07-15 16:12:00 |
|
Acrivon Therapeutics: Priced For Failure, Built For Precision
Acrivon Therapeutics (ACRV) trades below cash value, with the market deeply discounting its platform and pipeline despite promising early data. ACRV's AP3 platform enables precision patient-matching for kinase inhibitor therapies, showing a 50% response rate in serous endometrial cancer with ACR-368. Key near-term catalysts include Phase 2b ACR-368 data and Phase 1 ACR-2316 expansion results, both critical for de-risking and expanding commercial potential. seekingalpha.com - 2026-07-13 04:44:48 |
|
GE HealthCare advancing enterprise imaging with cloud-enabled solutions
GE HealthCare will showcase its latest enterprise imaging solutions at the Society for Imaging Informatics in Medicine (SIIM) 2026 Annual Meeting in Pittsburgh gurufocus.com - 2026-06-09 10:00:00 |
|
ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock
UNIONDALE, N.Y., May 27, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock. prnewswire.com - 2026-05-27 16:15:00 |
|
Are CPRX, UNF, RMAX, ACR Obtaining Fair Deals for their Shareholders?
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws prnewswire.com - 2026-05-12 02:56:00 |
|
ACRES Commercial Realty Investor Alert: Kahn Swick & Foti, LLC Investigates ACRES Commercial Realty Corp. - ACR
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the merger of ACRES Commercial Realty Corp. (NYSE: ACR) ("ACR" or the "Company") and ACRES Capital Corp. ("ACC") pursuant to which ACR will acquire ACC in an all-stock transaction. Under the terms of the proposed transaction, upon closing of the Merger, the Company will issue approximately 7.5 million shares of ACR'. businesswire.com - 2026-05-06 11:56:00 |
|
ACR Stock Alert: Halper Sadeh LLC is Investigating Whether ACRES Commercial Realty Corp. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of ACRES Commercial Realty Corp. (NYSE: ACR) and ACRES Capital Corp. Halper Sadeh encourages ACRES Commercial shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether ACRES Commercial and its board of directors violated. businesswire.com - 2026-05-04 10:03:00 |
|
REITs Excel, Earnings Swell, Fed Rebels
U.S. equity markets advanced for a fifth straight week - their longest winning streak since 2024 - as strong earnings, resilient data, and hopes for lasting Iran peace fueled optimism. Investors looked through another oil-price surge and inflationary pressure, focusing instead on corporate resilience and economic strength despite a complex macro backdrop shaped by geopolitical and policy uncertainty. The Fed held rates steady in an unusually fractured 8-4 vote, while Powell's plan to remain on the Board broke precedent and raised politically charged succession questions. seekingalpha.com - 2026-05-03 09:00:00 |
|
ACRES Commercial Realty Corp. (ACR) Q1 2026 Earnings Call Transcript
ACRES Commercial Realty Corp. (ACR) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-04-30 18:21:53 |
|
ACR.PR.D: A Large Yield From This REIT Preferred Equity
ACRES Commercial Realty has officially entered a definitive agreement to acquire its external manager, ACRES Capital Corp., in an all-stock transaction. This move transitions ACR to being internally managed. The merger is still subject to shareholder approval but would result in a much larger entity with a more diverse set of businesses. The Series D Preferred (ACR.PR.D) remains an attractive target for income-focused investors, sporting a current yield of 9.15%. seekingalpha.com - 2026-04-30 12:23:39 |
|
ACRES Commercial (ACR) Q1 Earnings Meet Estimates
ACRES Commercial (ACR) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.86 per share a year ago. zacks.com - 2026-04-30 08:41:11 |
|
ACRES COMMERCIAL REALTY CORP. REPORTS RESULTS FOR FIRST QUARTER 2026
UNIONDALE, N.Y., April 30, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. prnewswire.com - 2026-04-30 06:15:00 |
|
ACRES Commercial Realty Corp. Announces Agreement to Internalize Management and Acquire ACRES Capital Corp.
~Enhanced Earnings Profile –Significant Third-Party Revenue Streams~ ~Alignment of Interest and Consideration in Form of ACR Shares at Fully Diluted Book Value~ ~Continuity of Management Team~ UNIONDALE, N.Y., April 30, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) ("ACR" or the "Company") and ACRES Capital Corp. ("ACC") announced today that they have entered into a definitive merger agreement (the "Merger Agreement"), pursuant to which ACR will acquire ACC in an all-stock transaction (the "Merger"). prnewswire.com - 2026-04-30 06:14:00 |
|
Acres Commercial Realty: The High-Yielding Preferred Stock Could Be Interesting
Acres Commercial Realty focuses on first mortgage loans, with 80% of its portfolio backed by multifamily properties, and plans to expand its $2.2B asset base. ACR's preferred shares, particularly Series C, offer a 9.6% yield with floating rates, presenting an attractive risk/reward profile despite a modest dividend coverage ratio. Management's strong track record is evidenced by minimal realized loan losses—just $4.8M on $368M in troubled loans over five years. seekingalpha.com - 2026-04-28 10:30:00 |
|
Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities
Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition globenewswire.com - 2026-04-17 16:00:00 |